Nina Church joins as Executive Director of Global Clinical Development and Nancy Herje as Senior Director of Clinical Operations LONDON, June 25...
Ensifentrine delivery via MDI inhalers could dramatically expand clinical utility and commercial opportunity LONDON, June 04, 2019 (GLOBE...
LONDON, May 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
Verona Pharma PLC 29 May 2019 Verona Pharma plc PDMR Dealing May 29, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona...
Analysis confirms continued symptom benefits improving over time, supporting anti-inflammatory effects of ensifentrine in addition to...
LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
Nebulized ensifentrine as add-on to dual bronchodilator therapy for COPD demonstrated additional increase in lung function on top of maximum...
LONDON, May 02, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical stage...
LONDON, April 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a...
News) - Verona Pharma PLC on Tuesday said it secured a key patent from the European Patent Office relating to its lead ...
Bolsters patent estate for lead development candidate and provides expiry dates out to 2035 LONDON, April 09, 2019 (GLOBE NEWSWIRE) -- Verona...
LONDON, April 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.